Calyxo, a medical device company revolutionizing kidney stone treatment, has successfully closed a $40 million Series F financing round. The funding was co-led by Ally Bridge Group and Janus Henderson Investors, marking a significant vote of confidence in the company's technology. This financial milestone coincides with the treatment of over 40,000 patients with its innovative CVAC System, signaling strong market adoption.
Strategic Investment for Commercial Expansion
The financing round saw continued support from existing investors, including Questa Capital, Avidity Partners, and CRG, alongside the new lead investors. These proceeds are earmarked to significantly expand Calyxo's commercial infrastructure and accelerate market penetration. The company aims to make its advanced kidney stone treatment more widely available to urologists and their patients across the country.
A key focus for the new capital will be the generation of further clinical and health economic evidence for the CVAC System. Calyxo plans to initiate new studies evaluating long-term patient outcomes and the reduction in downstream healthcare utilization. This data will further substantiate the system's value proposition and support its integration into standard clinical practice.
A New Standard in Kidney Stone Treatment
The CVAC System is an all-in-one solution designed for a minimally invasive approach to kidney stone clearance. It employs continuous irrigation and vacuum aspiration to remove stone fragments effectively during and after laser lithotripsy procedures. This innovative method enables physicians to achieve a more complete, stone-free outcome for patients with greater efficiency.
Having treated over 40,000 patients, the CVAC System is transitioning from an emerging technology to an essential tool in urology. Its growing adoption is supported by a body of evidence demonstrating consistently low residual stone volume and improved procedural efficiency. These results are shifting the goal of kidney stone treatment toward achieving complete clearance as the measure of success.
Investor and Leadership Perspectives
Kevin Reilly, a Managing Director at Ally Bridge Group, expressed confidence in the company's direction and its differentiated technology. He noted that Calyxo is addressing a significant need in kidney stone treatment with a solution backed by strong clinical validation. The firm is excited to partner with the Calyxo team to build on their current momentum and market success.
Calyxo's CEO, Joe Catanese, described the financing as a pivotal moment for the company's growth trajectory. He stated that the extensive real-world experience, combined with clinical evidence, confirms the CVAC System is becoming a new standard of care. This investment will allow the company to accelerate innovation and expand its evidence base to further improve patient care.
Addressing a Widespread Health Issue
Kidney stone disease represents a widespread and costly health issue, affecting approximately one in ten people in the United States. The condition is not only painful for patients but also places a significant burden on the healthcare system. Projections estimate that the direct annual treatment costs for kidney stones will surpass $4.1 billion by the year 2030.
This $40 million capital infusion positions Calyxo to accelerate its mission of transforming kidney stone treatment for patients and physicians. The investment will fuel commercial growth, support robust clinical research, and drive continued innovation across the CVAC System platform. With strong investor backing, Calyxo is poised to solidify its leadership in providing safer and more effective urological solutions.